Cargando…

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma

BACKGROUND: Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drick, Nora, Milger, Katrin, Seeliger, Benjamin, Fuge, Jan, Korn, Stephanie, Buhl, Roland, Schuhmann, Maren, Herth, Felix, Kendziora, Benjamin, Behr, Juergen, Kneidinger, Nikolaus, Bergmann, Karl-Christian, Taube, Christian, Welte, Tobias, Suhling, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667509/ https://www.ncbi.nlm.nih.gov/pubmed/33204117 http://dx.doi.org/10.2147/JAA.S270298

Ejemplares similares

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
por: Drick, Nora, et al.
Publicado: (2022)

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
por: Drick, Nora, et al.
Publicado: (2018)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
por: Drick, Nora, et al.
Publicado: (2023)

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma
por: Franceschi, Elisa, et al.
Publicado: (2022)

Domestic Parasitic Infections in Patients with Asthma and Eosinophilia in Germany – Three Cases with Learnings in the Era of Anti- IL5 Treatments
por: Barnikel, Michaela, et al.
Publicado: (2023)

The impact of anti-eosinophilic therapy on exercise capacity and inspiratory muscle strength in patients with severe asthma
por: Franceschi, Elisa, et al.
Publicado: (2023)

Eosinophils, beyond IL-5
por: Esnault, Stephane, et al.
Publicado: (2021)

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
por: Suhling, Hendrik, et al.
Publicado: (2023)

Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor
Publicado: (1988)

Comparison of IL-33 and IL-5 family mediated activation of human eosinophils
por: Angulo, Evelyn L., et al.
Publicado: (2019)

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
por: Pitlick, Mitchell M., et al.
Publicado: (2022)

Mouse resident lung eosinophils are dependent on IL‐5
por: Dolitzky, Avishay, et al.
Publicado: (2022)

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?
por: Mümmler, Carlo, et al.
Publicado: (2020)

IL-5 and IL-6 are increased in the frontal recess of eosinophilic chronic rhinosinusitis patients
por: Kubota, Kazunori, et al.
Publicado: (2017)

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma
por: Plank, Pia Maria, et al.
Publicado: (2023)

Susceptibility to L. sigmodontis infection is highest in animals lacking IL-4R/IL-5 compared to single knockouts of IL-4R, IL-5 or eosinophils
por: Frohberger, Stefan J., et al.
Publicado: (2019)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
por: Bakakos, Agamemnon, et al.
Publicado: (2021)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)
por: Milger, Katrin, et al.
Publicado: (2023)

Schistosoma mansoni egg-induced early IL-4 production is dependent upon IL-5 and eosinophils
Publicado: (1996)

Pin1 Regulates IL-5 Induced Eosinophil Polarization and Migration
por: Shen, Zhong-Jian, et al.
Publicado: (2021)

EOSINOPHILS AND IL-5 RECEPTOR IN COVID-19 POSTMORTEM LUNG TISSUE
por: MCCRAE, CHRISTOPHER, et al.
Publicado: (2021)

Treating Acute Severe Eosinophilic Asthma with IL-5 Inhibitors in ICU
por: Barbarot, Nicolas, et al.
Publicado: (2022)

Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media
por: Chikumoto, Ayumi, et al.
Publicado: (2022)

Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism
por: Milger, Katrin, et al.
Publicado: (2015)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Zhang, Chuchu, et al.
Publicado: (2021)

CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 production
por: Rozenberg, Perri, et al.
Publicado: (2017)

The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review
por: Patterson, Megan F, et al.
Publicado: (2015)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

Presence of purpura is related to active inflammation in association with IL-5 in eosinophilic granulomatosis with polyangiitis
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Effects of prednisolone on eosinophils, IL-5, eosinophil cationic protein, EG2+ eosinophils, and nitric oxide metabolites in the sputum of patients with exacerbated asthma.
por: Jang, A. S., et al.
Publicado: (2000)

Chronic progressive pulmonary paracoccidioidomycosis in a female immigrant from Venezuela
por: Kayser, Moritz, et al.
Publicado: (2019)

Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series
por: Tashiro, Hiroki, et al.
Publicado: (2022)

IL-5 and GM-CSF, but Not IL-3, Promote the Proliferative Properties of Inflammatory-like and Lung Resident-like Eosinophils in the Blood of Asthma Patients
por: Palacionyte, Jolita, et al.
Publicado: (2022)

Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography
por: Götschke, Jeremias, et al.
Publicado: (2018)

Human differentiated eosinophils release IL-13 in response to IL-33 stimulation
por: Uchida, Amiko M., et al.
Publicado: (2022)

Cholesterol Selectively Regulates IL-5 Induced Mitogen Activated Protein Kinase Signaling in Human Eosinophils
por: Burnham, Mandy E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ckr10np26c55ae0eqsovuvnks3